High throughput sars-COV-2 binding antibody immunoassay for testing of clinical samples and variant assessment
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50122C00013
- Awardee
-
Laboratories Nexelis Canada Inc. UEI MBEZLEGWHUN5 Part of Nexelis Group Inc.
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $14,625,365
Award facts
- Opportunity
-
- High Throughput SARS-CoV-2 Binding Antibody Immunoassay for Testing of Clinical Samples and Variant Assessment Pre-Solicitation · 75A50122R00007 · Posted Nov 18, 2021
- Contract value 99% obligated
-
- $14,625,365.10 Current, with exercised options
- $14,725,965.10 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Seattle, WA 98119, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $8,155,375 | |
| Original award | $6,469,990 |
About this award
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $14.7 million firm fixed price definitive contract to Laboratories Nexelis Canada Inc., doing business as Pairimmune, to provide high throughput SARS-CoV-2 binding antibody immunoassay testing of clinical samples from COVID-19 vaccine trials. The contract supports assay development and validation for emerging SARS-CoV-2 variants. Per the solicitation, the one-year base period of performance is from January 2022 through July 2024. There is no set-aside. Funding comes from HHS to support its COVID-19 medical countermeasure programs. As the incumbent, Nexelis Laboratories Canada Inc. will leverage existing capabilities to analyze samples and assess variants under this new contract.
Quick answers
Who was awarded contract 75A50122C00013?
75A50122C00013 was awarded to Laboratories Nexelis Canada Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on January 1, 2022.
How much is contract 75A50122C00013 worth?
The government has obligated $14,625,365 on 75A50122C00013. Its potential value, with all options, is $14,725,965.
Was contract 75A50122C00013 competed?
The extent of competition for 75A50122C00013 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award